title: Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.
abstract: OBJECTIVE
  To compare whole-abdominal irradiation (WAI) and doxorubicin-cisplatin (AP) chemotherapy in women with stage III or IV endometrial carcinoma having a maximum of 2 cm of postoperative residual disease.
  
  
  METHODS
  Four hundred twenty-two patients were entered onto this trial. Of 396 assessable patients, 202 were randomly allocated to receive WAI, and 194 were allocated to receive AP. Irradiation dosage was 30 Gy in 20 fractions, with a 15-Gy boost. Chemotherapy consisted of doxorubicin 60 mg/m2 and cisplatin 50 mg/m2 every 3 weeks for seven cycles, followed by one cycle of cisplatin.
  
  
  RESULTS
  Most patient and tumor characteristics were well balanced. The median patient age was 63 years; 50% had endometrioid tumors. Median follow-up time was 74 months. The hazard ratio for progression adjusted for stage was 0.71 favoring AP (95% CI, 0.55 to 0.91; P < .01). At 60 months, 50% of patients receiving AP were predicted to be alive and disease free when adjusting for stage compared with 38% of patients receiving WAI. The stage-adjusted death hazard ratio was 0.68 (95% CI, 0.52 to 0.89; P < .01) favoring AP. Moreover, at 60 months and adjusting for stage, 55% of AP patients were predicted to be alive compared with 42% of WAI patients. Greater acute toxicity was seen with AP. Treatment probably contributed to the deaths of eight patients (4%) on the AP arm and five patients (2%) on the WAI arm.
  
  
  CONCLUSIONS
  Chemotherapy with AP significantly improved progression-free and overall survival compared with WAI. Nevertheless, further advances in efficacy and reduction in toxicity are clearly needed.
authors.affiliation: Leo W. Jenkins Cancer Center, Brody School of Medicine at East Carolina University, Greenville, NC, USA.
authors.forename: Marcus E
authors.initials: ME
authors.lastname: Randall
authors.forename: Virginia L
authors.initials: VL
authors.lastname: Filiaci
authors.forename: Hyman
authors.initials: H
authors.lastname: Muss
authors.forename: Nick M
authors.initials: NM
authors.lastname: Spirtos
authors.forename: Robert S
authors.initials: RS
authors.lastname: Mannel
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Fowler
authors.forename: J Tate
authors.initials: JT
authors.lastname: Thigpen
authors.forename: Jo Ann
authors.initials: JA
authors.lastname: Benda
mesh_terms: D000005:Abdomen / Q000528:radiation effects*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002423:Cause of Death; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011879:Radiotherapy Dosage; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D004317:Doxorubicin; D002945:Cisplatin